REVIEW ARTICLE

Requirements for improving health and well-being of children with Prader-Willi syndrome and their families

Jessica Mackay,1,2 Zoe McCallum,3,4 Geoffrey R Ambler,5 Komal Vora,6 Gillian Nixon,7,8,9 Philip Bergman,9,10 Nora Shields,11 Kate Milner,3,12 Nitin Kapur,13,14 Patricia Crock,6,15 Daan Caudri,1,16 Jaqueline Curran,17 Charles Verge,18,19 Chris Seton,20,21 Andrew Tai,22 Elaine Thom,23 Yassmin Musthaffa,24,25 Antony R Lafferty,26,27 Greg Blecher,28 Jessica Harper,29 Cara Schofield,1 Aleisha Nielsen,29 Andrew Wilson,3,29 Helen Leonard,1 Catherine S Choong1,17 and Jenny Downs1

1 Telethon Kids Institute, Centre for Child Health Research, 2 School of Medicine, University of Western Australia, 17 Department of Endocrinology, 29 Respiratory and Sleep Medicine, Perth Children's Hospital, 36 School of Physiotherapy and Exercise Science, Curtin University, Perth, Western Australia, Departments of 7 Neurodevelopment and Disability, and 4 Gastroenterology and Clinical Nutrition, Royal Children's Hospital, 7 Melbourne Children's Sleep Centre, and 10 Department of Paediatric Endocrinology and Diabetes, Monash Children's Hospital, 8 The Ritchie Centre, Department of Paediatrics, Monash University, 11 School of Allied Health, La Trobe University, 12 Centre for International Child Health, Murdoch Children's Research Institute, Melbourne, Victoria, 8 Institute of Endocrinology and Diabetes, Children's Hospital at Westmead, Departments of 16 Endocrinology, and 26 Sleep Medicine, Sydney Children's Hospital, 13 School of Women's and Children's Health, University of New South Wales, 18 Department of Sleep Medicine, Children's Hospital Westmead, 19 Woolcock Institute of Medical Research, Sydney University, Sydney, 4 Department of Paediatric Endocrinology and Diabetes, John Hunter Children's Hospital, 14 Hunter Medical Research Institute, University of Newcastle, Newcastle, New South Wales, 19 Respiratory and Sleep Medicine, Queensland Children's Hospital, 15 School of Clinical Medicine, 24 Diamantina Institute, Faculty of Medicine, and 25 Translational Research Institute, University of Queensland, Brisbane, Queensland, 16 Respiratory and Sleep Department, and 22 Endocrinology and Diabetes Department, Women's and Children's Hospital, Adelaide, South Australia, 20 Department of Endocrinology and Diabetes, Canberra Hospital, 27 Medical School, Australian National University, Canberra, Australian Capital Territory, Australia and 16 Erasmus University Medical Center, Rotterdam, the Netherlands

Abstract: Prader-Willi syndrome (PWS) is a rare genetic condition with multi-system involvement. The literature was reviewed to describe neurodevelopment and the behavioural phenotype, endocrine and metabolic disorders and respiratory and sleep functioning. Implications for child and family quality of life were explored. Challenging behaviours contribute to poorer well-being and quality of life for both the child and caregiver. Recent evidence indicates healthy outcomes of weight and height can be achieved with growth hormone therapy and dietary restriction and should be the current target for all individuals with PWS. Gaps in the literature included therapies to manage challenging behaviours, as well as understanding the effects of growth hormone on respiratory and sleep function. New knowledge regarding the transition of children and families from schooling and paediatric health services to employment, accommodation and adult health services is also needed. Developing a national population-based registry could address these knowledge gaps and inform advocacy for support services that improve the well-being of individuals with PWS and their families.

Key words: endocrine; hyperphagia; Prader-Willi syndrome; quality of life; sleep disordered breathing.

Key Points
1 Food-seeking activities, restrictive or repetitive behaviours and difficulties with social communication and reciprocity in individuals with Prader-Willi Syndrome have significant consequences for maternal and family well-being.
2 Growth hormone therapy has contributed to reduced obesity, but the optimal initiation, dosage and continuation of the therapy and its effect on respiratory and sleep regulation and function remains unclear.
3 Evidence for supportive therapies in Prader-Willi Syndrome is poor; development of evidence-based management and advocacy for affected families require a more comprehensive analysis of relevant covariates influencing quality of life in a large, population-based cohort.

Correspondence: Associate Professor Jenny Downs, Telethon Kids Institute, Perth Children’s Hospital, 15 Hospital Avenue, Nedlands, WA 6009, Australia. Fax: + 61 86319 1777; email: jenny.downs@telethonkids.org.au

Conflict of interest: None declared.
Accepted for publication 2 June 2019.

Prader-Willi syndrome (PWS) is a rare disorder affecting approximately 1 in 15,000 live births1,2 and results from a lack of expression of paternal genes in the 15q11-q13 region on chromosome 15. Overall life expectancy is shortened such that 13–20% of people with PWS have died by 35 years in previously published cohorts.3,4 Recent improvement in survival is attributed to earlier diagnosis and greater therapeutic intervention in delaying or preventing the onset of obesity.5
There are many challenges for affected children and their families. Appetite dysregulation, most notably hyperphagia, and the difficult behaviours exhibited by individuals with PWS necessitate high levels of supervision, environmental management and behavioural interventions from caregivers each day. Ongoing vigilance and management can lead to higher levels of distress and reduced quality of life for caregivers of individuals with PWS compared to caregivers of individuals with other chronic congenital conditions or the general population. This review will describe PWS, focusing on appetite dysregulation, respiratory function and sleep disordered breathing and challenging behaviours, and will explore their implications for child and family well-being and quality of life.

Methods

A review of the literature describing the health and well-being of individuals with PWS and their families was performed. The inclusion of family well-being was strongly endorsed as a component of our study by our Western Australian PWS Consumer Reference Group. Article titles and abstracts were searched in the following databases: Medline, PubMed, CINAHL and Google Scholar for PWS using variations of the following key terms: health, well-being, quality of life, life satisfaction, stress, coping, managing, meaningful, impact, psychosocial, values, burden, family functioning, family cohesion, support, response, strain, education, affective disorders, anxiety, depression and psychology. The references of relevant articles were also examined for inclusion in the review. Non-English articles were excluded.

Results

Genetic cause

PWS was initially described by Prader et al. in 1956, with the diagnostic criteria revised by consensus in 1993 and revised again in 2001 to inform clinical indications for genetic testing (Table 1). PWS results from the absence of functioning paternal genes on chromosome 15 in the 15q11-q13 region. The roles of these genes are not completely understood, but they are known to contribute to neural development and function, with their absence affecting multiple systems across the life-span (Fig. 1). Approximately 60–70% of all PWS cases result from de novo deletions on the paternally inherited chromosome 15 within this region, and a further 25–30% of PWS cases are associated with maternal uniparental disomy of chromosome 15. The remainder are associated with erroneous silencing and disrupting of the function of the paternally inherited genes in the q11-q13 region following defects, translocations or inversions in the imprinting centre located on the paternal chromosome 15.

Neurodevelopmental phenotype and challenging behaviours

Neonates with PWS may exhibit severe hypotonia, feeding difficulties resulting in the need for assisted feeding and failure to thrive. Other features seen during infancy include hypogonadism, mild craniofacial abnormalities such as a narrow bi-frontal diameter and almond shaped eyes and global developmental delay. Delayed motor development is observed in most (90–100%) children with PWS. Developmental milestones such as sitting and walking are usually achieved at approximately double the age of typically developing children. There are limited musculoskeletal data on strength and fitness, but some evidence indicates that physical activity programmes for primary school-aged children with PWS can increase daily physical activity. From 2 or 3 years of age, height velocity usually slows, and there can be excessive weight gain without strict dietary regulation. Children become increasingly obsessed with food, and the majority develop the hallmark characteristic of hyperphagia with loss of satiety.

Variable cognitive impairment affects most individuals with PWS, presenting as mild-to-moderate intellectual disability and delays in language development, particularly expressive language. However, intellectual functioning is classified as borderline normal in some individuals. Difficulties with social communication and reciprocity from early childhood are commonly reported for individuals with PWS, with difficulties in establishing social relationships also described in the literature.

The behavioural profile of PWS also includes restricted or repetitive behaviours. Combined with difficulties in social functioning, these behaviours are sufficient for a concurrent diagnosis of autism spectrum disorder in approximately a quarter (26.5%, n = 786) of individuals with PWS. Other problematic behaviours include emotional lability and temper tantrums, especially in response to interruption of food-seeking and repetitive behaviours; impediments to desired goals; changes to routines; or being presented with conflicting information, particularly pertaining to unjust deviation from social expectations. Comorbid psychiatric disorders can be common, for example, oppositional defiant disorder was diagnosed in 20% of 8- to 14-year-old

Table 1: Clinical indications for diagnostic testing of Prader-Willi syndrome (adapted from Gunay-Aygun et al., Cataletto et al. and Angulo et al.)

| Age at assessment | Clinical features prompting DNA testing |
|-------------------|----------------------------------------|
| Birth to 2 years  | Hypotonia with poor suck Reduced fetal movement Cryptorchidism |
| 2–6 years         | Hypotonia with a history of poor suck Global developmental delay Short stature and/or growth failure associated with accelerated weight gain Hypogonadism |
| 6–12 years        | Hypotonia Global developmental delay Excessive eating (hyperphagia, obsession with food) with central obesity if uncontrolled Short stature and/or decreased growth velocity |
| 13 years to adulthood | Cognitive impairment, usually mild intellectual disability Excessive eating (hyperphagia, obsession with food) with central obesity if uncontrolled Hypogonadism and/or typical behaviour problems (including temper tantrums and obsessive–compulsive features) Short stature and/or decreased growth velocity |
children with PWS (n = 61).19 Obsessive compulsive behaviours include obsessions with health-related issues and compulsions such as skin picking and rearranging objects in the environment for increased order.19 Mental health symptoms as indicated by scores above the clinical threshold for abnormal behaviours using the Developmental Behaviour Checklist have been observed in approximately three quarters of children and adolescents with PWS.20 Neurodevelopment and behaviour are also influenced by mutation; a meta-analysis of 744 individuals with PWS found that, in comparison to those with deletions, those with maternal uniparental disomy had higher intellectual quotient scores and greater prevalence of psychosis and bipolar disorders.21

Endocrine and metabolic phenotype

Hypothalamic pituitary axis dysfunction is implicated as the underlying disturbance in multiple manifestations of PWS (Fig. 1).12,22,23

Fig. 1 Characteristic clinical features of the Prader-Willi syndrome phenotype in infants and toddlers under 3 years of age and in children and adolescents aged 3 years and older. CVD, cardiovascular disease; T2DM, type 2 diabetes mellitus.
Growth hormone deficiency

Growth hormone (GH) deficiency is at least in part responsible for the characteristic clinical features of reduced growth velocity, muscle strength, low energy expenditure and obesity in PWS.\(^2\)\(^{-}\)\(^{24}\) GH therapy improves growth velocity and adult height for individuals affected by PWS and maintains lean body mass with age regardless of GH secretory status at baseline.\(^2\)\(^{-}\)\(^{24}\)\(^{25}\) The benefits of initiating GH therapy have been demonstrated for infants as young as 2–4 months of age and through early childhood.\(^2\)\(^6\) Currently, many children with PWS receive GH therapy, which lowers the body mass index (BMI) and, on average, provides the capacity to maintain BMI below two standard deviations above the age- and gender-matched reference values of the British 1990 normative growth charts for the duration of therapy.\(^2\)\(^{23}\)\(^{27}\)

Other benefits appear to include improved cognition\(^2\)\(^{3}\) and behaviour\(^2\)\(^{9}\) and improved motor strength and function.\(^3\)\(^{0}\) There is emerging evidence of the beneficial effects of continuing GH treatment into adulthood, with sustained improvements in body composition, and deterioration of these parameters when GH is discontinued after the attainment of adult height.\(^1\)\(^{3}\) However, as most adults with PWS do not meet the consensus criteria for adult GH deficiency, they are not eligible for subsidised GH replacement in many jurisdictions, including Australia. The physiological effects of cessation of GH therapy at 18 years of age after many years of continuous therapy during childhood and adolescence are not yet well characterised.

Metabolic disturbances and obesity-related sequelae

From birth, children with PWS have an abnormal body composition with increased fat mass and reduced lean muscle mass. Without strictly supervised caloric restriction and regular exercise, appetite disturbances and physical difficulties predispose the majority of children to childhood obesity. The Danish National Patient Registry database reported that individuals with PWS (n = 155) were 10 times more likely to be obese and 9 times more likely to be diagnosed with type 2 diabetes mellitus than the matched general population (n = 15 500).\(^1\)\(^{2}\) The development of obesity and impaired glucose metabolism are linked to various aspects of hypothalamic pituitary axis dysfunction. Abnormalities in hormones influencing appetite regulation and satiety signalling, such as ghrelin or peptide YY, may contribute to the hyperphagia in PWS.\(^2\)\(^{-}\)\(^{23}\) Obesity contributes to the increased risk of obstructive sleep apnoea, cardiovascular disease, reduced bone mineral density and fracture and scoliosis observed in patients with PWS.\(^2\)\(^{-}\)\(^{32}\)\(^{33}\)

Hypogonadism

Hypothalamic pituitary axis dysfunction also affects sexual development through hypogonadism, which usually manifests at birth. Almost all males with PWS have unilateral or bilateral cryptorchidism, although hypoplasia of the labia minora and clitoris in girls is less uniformly reported.\(^2\)\(^{2}\)\(^{2}\) Many children will commence puberty spontaneously but will have incomplete pubertal progression or maintenance without hormone replacement therapy. This results in infertility for nearly all individuals with PWS, although there have been isolated case reports of pregnancies in PWS.\(^2\)\(^{-}\)\(^{23}\) Untreated hypogonadism contributes to central adiposity and reduced vertebral bone mineral density.\(^2\)\(^{-}\)\(^{24}\) Sex steroid hormone replacement therapy has important benefits of improving linear growth, bone health and muscle mass and may improve the emotional well-being of adolescents with PWS.\(^3\)\(^{4}\)

Central hypothyroidism

Cross-sectional studies have reported hypothyroidism in 72.2% of infants under 2 years of age.\(^3\)\(^{5}\) 6–24% of children and adolescents\(^3\) and at rates similar to the general population in adults with PWS.\(^3\)\(^{7}\) Longitudinal research assessing the natural course of thyroid levels with a standard approach is required to determine the prevalence of central hypothyroidism across the life-span of individuals affected by PWS and for comparison with the general population. GH therapy may unmask central hypothyroidism in children with PWS, and annual surveillance is recommended.\(^3\)\(^{8}\)

Adrenocorticotrophic hormone insufficiency

Diagnostic tests and criteria for defining central adrenal insufficiency vary, resulting in a reported prevalence of central adrenal insufficiency in PWS ranging from 0 to 60%, with the majority of reports suggesting that it is closest to 10%.\(^3\)\(^{9}\) Inadequate adrenal response to stress has been suggested as one reason for reduced clinical symptoms observed in individuals with PWS when unwell, and has been hypothesised as a cause of unexplained acute deaths in childhood in PWS.\(^4\)\(^{0}\) The true prevalence of adrenal insufficiency and the subsequent potential for adrenal crisis in individuals with PWS is currently uncertain.\(^1\)\(^{9}\)

Appetite dysregulation

PWS is characterised by an age-dependent spectrum of appetite dysregulation, ranging from neonatal feeding difficulties with failure to thrive in infancy to the development of hyperphagia and subsequent obesity. By maintaining clinical records of weight gain and eating behaviours over a 10-year period (n = 58), Miller et al.\(^4\)\(^{1}\) observed that children with PWS fell into one of five phases of altered feeding patterns and growth.

| Phase | Start of phase age range | Description |
|-------|--------------------------|-------------|
| 0     | In utero                 | Maternal descriptions of reduced fetal movement, lower birthweight and length |
| 1a    | Birth                    | Difficulty feeding, poor appetite and weight gain |
| 1b    | 5–15 months              | Improved appetite, begins to gain weight along an expected growth curve |
| 2a    | 18–36 months             | Weight crosses curves, no significant increase in appetite or food intake |
| 2b    | 3–5 years                | Increased interest in food, greater appetite and caloric intake of food. Children become overweight or obese without dietary intervention |
| 3     | Pre-school – teens       | Hyperphagia, loss of satiety, obesity without dietary intervention |
| 4     | >20 years (rare)         | Regain capacity for satiety, hyperphagia declines or disappears |

Table 2 General phases of altered feeding patterns and growth in Prader-Willi syndrome (adapted from phases described by Miller et al.\(^4\)\(^{1}\))
et al. identified seven distinct phases of appetite dysregulation as summarised in Table 2.41 Without dietary regulation and control over access to food, obesity is likely and usually retained over the life-span of individuals with PWS.41

Butler et al.42 found that, despite receiving a diet restricted to 60–80% of normal caloric intake for age and activity, their cohort of children with PWS who did not receive GH (n = 120, aged 3–18 years) had weights varying between the normative 50th centile and above the 97th centile on normative growth charts generated from national growth data by the Centers for Disease Control and Prevention. They also observed that the normative 50th height centile varied between the 75th and 97th growth centiles for their cohort with PWS. These observations suggest that children with PWS have lower caloric requirements for weight maintenance compared with unaffected age-matched peers. Thus, dietary regulation remains an important aspect of management throughout the life-span.43 However, in addition to lower energy intake, attention to macronutrient composition and adequate levels of fibre, vitamin and micronutrients is important.44 Children for whom diet is regulated to avoid obesity should be monitored with respect to linear growth.

Hyperphagia may also be associated with inadequate chewing and eating unusual foods and non-food items, contributing to a greater risk of choking and respiratory aspiration.45,46 Poor oromotor co-ordination and gag reflexes, hypotonia and difficulties producing an adequate cough to expel excess secretions or airway foreign bodies could further explain these increased risks.45–47 Recent videofluoroscopy swallow studies suggest aspiration is common and often silent in infants with PWS.48 Examination of family-reported mortality data between 1973 and 2015 for 312 individuals with PWS in USA found that gastrointestinal problems (e.g. perforation), choking and accidents presumed related to food-seeking behaviours accounted for 22% of deaths (10, 6 and 6%, respectively).35

**Respiratory and sleep phenotype**

Craniofacial abnormalities (Fig. 1) and a small naso- and oropharynx are common in affected individuals, resulting in a relatively narrow upper airway.49 The presence of obesity can further increase upper airway resistance and is another well-known risk factor for obstructive sleep apnoea syndrome.50 Obstructive sleep apnoea is found in almost 80% of children with PWS,39 and those with moderate to severe obstructive sleep apnoea exhibit more hypoventilation and more severe desaturation during sleep than typically developing children with a similar severity of obstructive sleep apnoea.30 This may partly result from decreased respiratory reserve and increased work of breathing in PWS children related to altered ventilatory responses to hypoxia and hypercapnia or comorbidities of obesity and scoliosis.56 Consequently, children with obstructive sleep apnoea related to PWS may be at greater risk of developing obesity hypoventilation syndrome than other individuals with a similar level of obesity.

Central sleep apnoea is also frequently reported in PWS, particularly in children younger than 2 years of age.51 Contributors to central sleep apnoea include respiratory muscle hypotonia, abnormal arousal and ventilatory control mechanisms and may also be a downstream effect of hypothalamic dysfunction related to hypocretin deficiencies.45,56 The presence of excessive daytime sleepiness in individuals with PWS in the context of adequate quality and quantity of sleep, even in the absence of or sufficient treatment for sleep disordered breathing and hypothyroidism, suggests hypersomnolence is related to hypothalamic dysfunction, particularly hypocretin (also known as orexin) deficiencies, causing a narcolepsy phenotype with or without cataplexy.45,46

GH treatment can have varied impacts on sleep disordered breathing. GH may worsen obstructive sleep apnoea syndrome symptoms by stimulating adenotonsillar and retropharyngeal lymphoid tissue growth, but on the other hand, symptoms could be alleviated by the beneficial effects of GH on body composition.52 Although previous observational studies could not demonstrate a consistent increase in obstructive sleep apnoea, it is advised to regularly screen children with PWS on GH using polysomnography due to the risk of progressive obstructive sleep apnoea syndrome in some individuals with potentially severe sequelae.53 Furthermore, studies to date indicate that GH supplementation may be associated with a reduction in central sleep apnoea, but the observational nature of these studies makes it difficult to differentiate improvements due to the natural history of PWS from effects caused by GH.51

**Well-being and quality of life**

Focus in the literature on neurodevelopmental disorders is shifting to better understand the lived experiences of affected children and their quality of life. The phenotype of PWS is associated with a complex set of physical and psychological needs that challenge the child’s daily living, particularly in relation to hyperphagia, social functioning and behavioural difficulties. For example, leisure activities for 123 individuals with PWS (4–48 years) frequently included watching television, particularly those with compulsive behaviours, with limited physical play and activities, particularly those with greater BMI values.54 Quality of life is a broad descriptor of well-being, and compared with typically developing children, physical, social and mental functioning scores have been reported to be lower for children with PWS (n = 9 younger than 14 years, n = 20 older than 14 years).55 Similar differences, particularly for psychosocial functioning, have also been observed, with children with PWS (n = 44) receiving lower scores than children with obesity but not PWS.56 A randomised controlled trial evaluating the effects of GH for children with PWS (n = 26, median (interquartile range) age 8 (7–11 years)) found that benefits for physical functioning were accompanied by better quality of life, which was sustained over an 11-year follow-up period.57 There is, nevertheless, limited literature on the quality of life in PWS, with interpretation hampered by small sample sizes, use of different measurement tools and lack of multivariate models investigating the determinants of quality of life.

Longer-term social outcomes are of interest to those managing children with PWS who will transition to adult care with time, but the literature in this area is particularly scant. While poorer executive and social functioning has been associated with poorer academic attainment,15 indicators for employment and accommodation outcomes are not understood. One UK survey published in 1990 found heterogeneous outcomes with 1 in 6 of 61 young adults with PWS achieving employment, albeit in most cases, this was in ‘sheltered’ employment.58 Current data across a
population are unknown but are of critical importance for family counselling and for the planning of health and disability supports during and after the transition period from paediatric to adult health services and other supports.

**Family and caregiver well-being**

Common challenges for caregivers of children with special needs include child sleep disturbances and behavioural and emotional problems, which place demands on caregiver resources and a great strain on family relationships and functioning. Delays in diagnosis and accessing ongoing treatments and supports leads to substantial parental stress in many rare genetic disorders. A high prevalence of child sleep disturbances leads to insufficient and disrupted sleep for caregivers, compounding the management of daytime challenging behaviours. Caregiver demands in PWS also include intensive supervision due to the need to limit access to food. Excessive food-seeking behaviours have been negatively correlated with maternal life satisfaction (n = 123; r = −0.25, P = 0.001) and are associated with higher levels of family stress. Greater availability of food outside the home environment and difficulties in accessing timely respite with carers who have an adequate understanding of PWS may also restrict social activities. Interviews with mothers of children with PWS (n = 8) exploring parental stress and coping identified concerns related to meeting their own personal needs and difficulties coordinating education, work placement and other supports from service agencies for their child. Siblings of children with PWS may also experience substantial stress, and necessary supports for them have not been explored.

There is a complex interplay between child and parental well-being. Studies examining this relationship in other chronic childhood conditions have found that challenging child behaviours negatively affected maternal well-being, and maternal depressive symptoms in turn negatively impacted the future behaviour of the child. Research over relatively short time frames has found each to be predictive of the other over 10 months (n = 72) and 2 years (n = 175). Further research is required to confirm causality and mediating factors within these complex relationships. Current evidence is an insufficient foundation for advocacy and service provision for affected families.

**Discussion**

PWS is a genetic condition with multiple neurodevelopmental features and comorbidities necessitating ongoing medical and behavioural supervision, intensive management and extensive lifestyle modification by caregivers and families of affected individuals. Current comprehensive and multidisciplinary care using GH and dietary management can help the child with PWS achieve BMI values within normal range, and this is a clinical goal. We have identified gaps in the understanding of musculoskeletal functioning, physical activity and swallowing dysfunction and uncertainty on the effects of GH on respiratory and sleep functioning. GH was approved as a treatment for PWS in 2011, yet guidelines regarding age of initiation, dosage and continuing GH therapy beyond reaching adult height have not been established, producing cohorts with variable use of GH therapy. There is a relatively high prevalence of mental health symptoms, including challenging behaviours, that demands systematic evaluation and management, with implications for child and family well-being and functioning.

---

**Fig. 2** Model of the determinants and modifiable pathways at the individual, social and socio-economic levels that influence quality-of-life outcomes for children and families affected by Prader-Willi syndrome.
Child and family functioning are intertwined, and the symptoms of PWS can threaten both the child’s and caregiver’s quality of life. Most studies examining the quality of life for individuals with PWS and their caregivers thus far are limited in the generalisability of their results due to sample sizes or by limited accounting for important covariates. For example, poor sleep, challenging behaviours and the impacts of services to support individuals with PWS and their families are largely omitted from analyses. There have been no studies on school functioning or transition from paediatric to adult health services, and data on young adult employment and accommodation are sparse.

There have been limited Australian studies of PWS.\(^1\)\(^\text{3,7,25,26,62}\) This gap is particularly relevant for Australian families with the rollout of the National Disability Insurance Scheme where caregivers must provide evidence of therapeutic benefit from supports and services to receive funding for their child. Emotional and educational support from parent support groups has been suggested to moderate the social isolation and reduced quality of life for caregivers with individuals with other chronic conditions\(^60\) but has not been examined in PWS. The Prader-Willi Research Foundation and the Prader-Willi Syndrome Association in Australia are two examples of resources utilised by caregivers for individuals with PWS. Guidance on the implementation of comprehensive multi-disciplinary clinics for PWS warrants investigation, including ensuring equity of access for rural and remote families.

We propose that existing gaps in the literature can be addressed by the development of an Australian population-based registry to enable: (i) capture of phenotypic variability; and (ii) inclusion of a comprehensive set of variables with relevant covariates for the evaluation of child and family outcomes (Fig. 2). Successful examples in Australia include the Victorian Cerebral Palsy Registry, which includes individuals born or living in Victoria with cerebral palsy since 1970,\(^69\) and the Australian Rett Syndrome Database, which ascertains individuals with Rett syndrome born since 1976,\(^70\) each capturing a population for surveillance and comprehensive research programmes. To this end, we have initiated the process of creating an Australasian PWS Registry to enable a population-based analysis of variations in phenotype, the treatments and resources available to support the needs of children with PWS and their families and subsequent impacts on child and caregiver quality of life.

Acknowledgements

This work is supported by a Prader Willi Association USA 2016 Research Grant to CS Choong, D Caudri and A Wilson and a Perth Children’s Hospital Foundation 2018 to CS Choong, J Downs, D Caudri, H Leonard and G Nixon. We acknowledge the advice of the Western Australian PWS Consumer Reference Group. We thank Ms Gillian Northcott from Medical Illustrations at Perth Children’s Hospital for the assistance with digital artwork.

References

1. Lionti T, Reid SM, White SM, Rowell MM. A population-based profile of 160 Australians with Prader-Willi syndrome: Trends in diagnosis, birth prevalence and birth characteristics. Am. J. Med. Genet. A 2015; 167A: 371–8.
2. Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi syndrome. In: GeneReviews. Seattle, WA: University of Washington; 1998. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1330/ [accessed 16 May 2019].
3. Lionti T, Reid SM, Rowell MM. Prader-Willi syndrome in Victoria: Mortality and causes of death. J. Paediatr. Child Health 2012; 48: 506–11.
4. Grugni G, Crino A, Bosio L et al. The Italian National Survey for Prader-Willi syndrome: An epidemiologic study. Am. J. Med. Genet. A 2008; 146A: 861–72.
5. Manzano AM, Loker J, Heinemann J, Loker C, Butler MG. Survival trends from the Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genet. Med. 2018; 20: 24–30.
6. Lanfranchi S, Vianello R. Stress, locus of control, and family cohesion and adaptability in parents of children with down, Williams, fragile X, and Prader-Willi syndromes. Am. J. Intellect. Dev. Disabil. 2012; 117: 207–24.
7. Thomas A, Glasson E, Roberts P, Bittles A. “Over time it just becomes easier...”: Parents of people with Angelman syndrome and Prader–Willi syndrome speak about their carer role. Disabil. Rehabil. 2017; 39: 763–70.
8. Kayadanian N, Schwartz L, Farrar E, Comtois KA, Strong TV. High levels of caregiver burden in Prader-Willi syndrome. PLoS One 2018; 13: 1–15.
9. Prader A, Labhart A, Willi H. Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchismus und Oligophrenie nach myatonieartigem Zustand im Neugeborenenalter. Schweiz. Med. Wochenschr. 1956; 86: 1260–1.
10. Holm VA, Cassidy SB, Butler MG et al. Prader-Willi syndrome: Consensus diagnostic criteria. Pediatrics 1993; 91: 398–402.
11. Gunay-Aygun M, Schwartz S, Heeger S, O’Riordan MA, Cassidy SB. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics 2001; 108: E92.
12. Angulo MA, Butler MG, Catalotto ME. Prader-Willi syndrome: A review of clinical, genetic, and endocrine findings. J. Endocrinol. Invest. 2015; 38: 1249–63.
13. Reus L, Zwarts M, van Vlimmeren LA, Willemsen MA, Otten BJ, Nijhuis-van der Sanden MW. Motor problems in Prader-Willi syndrome: A systematic review on body composition and neuromuscular functioning. Neurosci. Biobehav. Rev. 2011; 35: 956–69.
14. Schlumpf M, Elholzer U, Gygax M, Schmid S, van der Stuijs I, l’Allemant D. A daily comprehensive muscle training programme increases lean mass and spontaneous activity in children with Prader-Willi syndrome after 6 months. J. Pediatr. Endocrinol. Metab. 2006; 19: 65–74.
15. Whittington J, Holland A. Cognition in people with Prader-Willi syndrome: Insights into genetic influences on cognitive and social development. Neurosci. Biobehav. Rev. 2017; 72: 153–67.
16. Dimitropoulos A, Ho A, Feldman B. Social responsiveness and competence in Prader-Willi syndrome: Direct comparison to autism spectrum disorder. J. Autism Dev. Disord. 2013; 43: 103–13.
17. Baker EK, Godler DE, Bui M et al. Exploring autism symptoms in an Australian cohort of patients with Prader-Willi and Angelman syndromes. J. Neurol. Disord. 2018; 10: 24.
18. Bennett JA, Germani T, Haqq AM, Zwaigenbaum L. Autism spectrum disorder in Prader-Willi syndrome: A systematic review. Am. J. Med. Genet. A 2015; 167A: 2936–44.
19. Lo ST, Collin PI, Hokken-Koelega AC. Psychiatric disorders in children with Prader-Willi syndrome-results of a 2-year longitudinal study. Am. J. Med. Genet. A 2015; 167A: 983–91.
20. Dykens EM, Kasari C. Maladaptive behavior in children with Prader-Willi syndrome, down syndrome, and nonspecific mental retardation. Am. J. Ment. Retard. 1997; 102: 228–37.
21. Yang L, Zhan GD, Ding JJ et al. Psychiatric illness and intellectual disability in the Prader-Willi syndrome with different molecular defects – A meta analysis. PLoS One 2013; 8: e72640.
22. Emerick JE, Vogt KS. Endocrine manifestations and management of Prader-Willi syndrome. Int. J. Pediatr. Endocrinol. 2013; 2013: 14.
23 Heksch R, Kamboj M, Anglin K, Obyrnia K. Review of Prader-Willi syndrome: The endocrine approach. Transl Pediatr 2017; 6: 274–85.

24 Deal CL, Tony M, Hobyre C et al. Growth Hormone Research Society workshop summary: Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 2013; 98: E1072–87.

25 Scheeremeyer E, Hughes I, Harris M et al. Response to growth hormone treatment in Prader-Willi syndrome: Auxological criteria versus genetic diagnosis. J. Paediatr. Child Health 2013; 49: 1045–51.

26 Scheeremeyer E, Harris M, Hughes I et al. Low dose growth hormone treatment in infants and toddlers with Prader-Willi syndrome is comparable to higher dosage regimes. Growth Horm. IGF Res. 2017; 34: 1–7.

27 Bakker NE, Lindberg A, Heissler J et al. Growth hormone treatment in children with Prader-Willi syndrome: Three years of longitudinal data in prepubertal children and adult height data from the KIGS database. J. Clin. Endocrinol. Metab. 2017; 102: 1702–11.

28 Bakker NE, Kuppens RJ, Siemensma EP et al. Eight years of growth hormone treatment in children with Prader-Willi syndrome: Maintaining the positive effects. J. Clin. Endocrinol. Metab. 2013; 98: 4013–22.

29 Lo ST, Siemensma EP, Festen DA, Collin PJ, Hokken-Koelega AC. Behavior in children with Prader-Willi syndrome before and during growth hormone treatment: A randomized controlled trial and 8-year longitudinal study. Eur. Child Adolesc. Psychiatry 2015; 24: 1091–101.

30 Carrel AL, Myers SE, Whitman BY, Eickhoff J, Allen DB. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 2010; 95: 1131–6.

31 Kuppens RJ, Bakker NE, Siemensma EP et al. Beneficial effects of GH in young adults with Prader-Willi syndrome: A 2-year crossover trial. J. Clin. Endocrinol. Metab. 2016; 101: 4110–6.

32 Hedegman E, Ulrichsen SP, Carter S et al. Long-term health outcomes in patients with Prader–Willi syndrome: A nationwide cohort study in Denmark. Int. J. Obes. 2017; 41: 1531–8.

33 Butler MG, Manzardo AM, Heinemann J, Loker C, Loker J. Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genet. Med. 2017; 19: 635–42.

34 Bakker NE, Kuppens RJ, Siemensma EPC et al. Bone mineral density in children and adolescents with Prader-Willi syndrome: A longitudinal study during puberty and 9 years of growth hormone treatment. J. Clin. Endocrinol. Metab. 2015; 100: 1609–18.

35 Vaiani E, Herzovich V, Chaler E et al. Thyroid axis dysfunction in patients with Prader-Willi syndrome during the first 2 years of life. Clin. Endocrinol. 2010; 73: 546–50.

36 Diene G, Mimoun E, Feigeriova E et al. Endocrine disorders in children with Prader-Willi syndrome – Data from 142 children of the French database. Horm. Res. Paediatr. 2010; 74: 121–8.

37 Butler MG, Theodoro M, Skoude JD. Thyroid function studies in Prader-Willi syndrome. Am. J. Med. Genet. A 2007; 143A: 489–92.

38 Mustaffa Y, Scheeremeyer E, Hughes I, Harris M, Leong G, Crock P. Changes to thyroid function (T4) following growth hormone (GH) therapy in children with Prader-Willi syndrome (PWS). J. Paediatr. Child Health 2019; 55: 5.

39 Oto Y, Matsubara K, Ayabe T et al. Delayed peak response of cortisol to insulin tolerance test in patients with Prader–Willi syndrome. Ann. J. Med. Genet. A 2018; 176: 1369–74.

40 de Lind van Wijngaarden RFA, Otten BJ, Festen DAM et al. High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 2008; 93: 1649–54.

41 Miller JL, Lynn CH, Driscoll DC et al. Nutritional phases in Prader-Willi syndrome. Am. J. Med. Genet. A 2011; 155A: 1040–9.

42 Butler MG, Lee J, Manzardo AM et al. Growth charts for non-growth hormone treated Prader-Willi syndrome. Pediatrics 2015; 135: e126–35.

43 McCandless SE; The Committee on Genetics. Health supervision for children with Prader-Willi syndrome. Pediatrics 2011; 127: 195–204.

44 Mackenzie ML, Triador L, Gill JK et al. Dietary intake in youth with Prader-Willi syndrome. Am. J. Med. Genet. A 2018; 176: 2309–17.

45 Gillett ES, Perez IA. Disorders of sleep and ventilatory control in Prader-Willi syndrome. Diseases 2016; 4: 23.

46 Tan HL, Urquhart DS. Respiratory complications in children with Prader Willi syndrome. Paediatr. Respir. Rev. 2017; 22: 52–9.

47 Stevenson DA, Heinemann J, Angulo M et al. Deaths due to choking in Prader–Willi syndrome. Am. J. Med. Genet. A 2007; 143A: 484–7.

48 Gross RD, Gisser R, Cherpes G, Hartman K, Maheshwary R. Subclinical dysphagia in persons with Prader–Willi syndrome. Am. J. Med. Genet. A 2017; 173: 384–94.

49 Sedky K, Bennett DS, Pumariaga A. Prader Willi syndrome and obstructive sleep apnea: Co-occurrence in the pediatric population. J. Clin. Sleep Med. 2014; 10: 403–9.

50 Abel F, Tan HL, Negro V et al. Hyponaedilation disproportionate to OSAS severity in children with Prader-Willi syndrome. Arch. Dis. Child. 2019; 104: 166–71.

51 Cohen M, Hamilton J, Naranj I. Clinically important age-related differences in sleep related disordered breathing in infants and children with Prader-Willi syndrome. PloS One 2014; 9: e101012.

52 Whitman BY, Myers SE. Prader-Willi syndrome and growth hormone therapy: Take a deep breath and weigh the data. J. Pediatr. 2013; 162: 224–6.

53 Berini J, Spica Russotto V, Castelnuovo P et al. Growth hormone therapy and respiratory disorders: Long-term follow-up in PWS children. J. Clin. Endocrinol. Metab. 2013; 98: E1516–E23.

54 Dykens EM. Leisure activities in Prader-Willi syndrome: Implications for health, cognition and adaptive functioning. J. Autism Dev. Disorder. 2014; 44: 294–302.

55 Caliandro P, Grugni G, Padua L et al. Quality of life assessment in a sample of patients affected by Prader-Willi syndrome. J. Paediatr. Child Health 2007; 43: 826–30.

56 Wilson KS, Wiersma LD, Rubin DA. Quality of life in children with PraderWilli syndrome: Parent and child reports. Res. Dev. Disabil. 2016; 57: 149–57.

57 Bakker NE, Siemensma EP, van Rijn M, Festen DA, Hokken-Koelega AC. Beneficial effect of growth hormone treatment on health-related quality of life in children with Prader-Willi syndrome: A randomized controlled trial and longitudinal study. Horm. Res. Paediatr. 2015; 84: 231–9.

58 Waters J, Clarke DJ, Corbett JA. Educational and occupational outcome in Prader-Willi syndrome. Child Care Health Dev. 1990; 16: 271–82.

59 Lee MH, Park C, Matthews AK, Hsieh K. Differences in physical health, and health behaviors between family caregivers of children with and without disabilities. Disabil. Health J. 2017; 10: 565–70.

60 Isa SN, Ishak I, Ab Rahman A. Nutritional phases in Prader-Willi syndrome. Asian J. Psychiatr. 2016; 19: 565.

61 Anderson M, Elliott EJ, Zurynski YA. Australian families living with rare disease: Experiences of diagnosis, health services use and needs for psychosocial support. Orphanet J. Rare Dis. 2013; 8: 22.

62 Nixon GM, Brouillette RT. Sleep and breathing in Prader-Willi syndrome. Pediatr. Pulmonol. 2002; 34: 209–17.
63 Cataletto M, Angulo M, Hertz G, Whitman B. Prader-Willi syndrome: A primer for clinicians. *Int. J. Pediatr. Endocrinol.* 2011; 2011: 12.

64 Shivers CM, Leonczyk C, Dykens E. Life satisfaction among mothers of individuals with Prader-Willi syndrome. *J. Autism Dev. Disord.* 2016; 46: 2126–37.

65 Mazaheri MM, Rae-Seeback RD, Preston HE et al. The impact of Prader–Willi syndrome on the family’s quality of life and caregiving, and the unaffected siblings’ psychosocial adjustment. *J. Intellect. Disabil. Res.* 2013; 57: 861–73.

66 Klinnert MD, Kaugars AS, Strand M, Silveira L. Family psychological factors in relation to children’s asthma status and behavioral adjustment at age 4. *Fam. Process* 2008; 47: 41–61.

67 Osborne LA, Reed P. The relationship between parenting stress and behavior problems of children with autistic spectrum disorders. *Except. Child.* 2009; 76: 54–73.

68 Woodman AC, Mawdsley HP, Hauser-Cram P. Parenting stress and child behavior problems within families of children with developmental disabilities: Transactional relations across 15 years. *Res. Dev. Disabil.* 2015; 36C: 264–76.

69 Meehan E, Freed GL, Reid SM et al. Tertiary paediatric hospital admissions in children and young people with cerebral palsy. *Child Care Health Dev.* 2015; 41: 928–37.

70 Leonard H, Bower C, English D. The prevalence and incidence of Rett syndrome in Australia. *Eur. Child Adolesc. Psychiatry* 1997; 6 (Suppl. 1): 8–10.
Author/s:
Mackay, J; McCallum, Z; Ambler, GR; Vora, K; Nixon, G; Bergman, P; Shields, N; Milner, K; Kapur, N; Crock, P; Caudri, D; Curran, J; Verge, C; Seton, C; Tai, A; Tham, E; Musthaffa, Y; Lafferty, AR; Blecher, G; Harper, J; Schofield, C; Nielsen, A; Wilson, A; Leonard, H; Choong, CS; Downs, J

Title:
Requirements for improving health and well-being of children with Prader-Willi syndrome and their families

Date:
2019-09-01

Citation:
Mackay, J., McCallum, Z., Ambler, G. R., Vora, K., Nixon, G., Bergman, P., Shields, N., Milner, K., Kapur, N., Crock, P., Caudri, D., Curran, J., Verge, C., Seton, C., Tai, A., Tham, E., Musthaffa, Y., Lafferty, A. R., Blecher, G., ... Downs, J. (2019). Requirements for improving health and well-being of children with Prader-Willi syndrome and their families. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 55 (9), pp.1029-1037. https://doi.org/10.1111/jpc.14546.

Persistent Link:
http://hdl.handle.net/11343/249876

File Description:
published version

License:
CC BY-NC-ND